Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Treatment Strategy of a Patient With a Brain Arteriovenous Malformation and Cranial Dural Fistula: 2-Dimensional Operative Video
Sattur, Mithun G. , Abi-Aad, Karl R., Tian, Fucheng, Welz, Matthew E., Anderies, Barrett J. , Anderies, Barrett, Bendok, Bernard R.

Mayo Clinic

Operative Neurosurgery | September 6, 2018 | Volume: 16 | Issue: 5 | Pages: 636-636

10.1093/ons/opy208 | PMID 30202995 Get It

Abstract We present the case of a 56-yr-old right-handed male, after informed consent was obtained, who presented with acute confusion and agitation, on the background of a remote history of an uncomplicated resection of a left parietal grade 2 glioma. Imaging revealed a large, acute right temporal intracerebral hemorrhage (ICH). Standard vascular workup for the cause of the ICH included catheter angiography. No direct cause of the hemorrhage was revealed; however, a high grade parasagittal dural arteriovenous fistula (DAVF) with cortical venous reflux was noted close to the prior craniotomy site. The venous reflux was towards the left hemisphere, but it was hypothesized that similar reflux on the right side may have been present and was not presently evident due to thrombosis. The DAVF was embolized by endovascular means, followed by evacuation of the hematoma. Follow-up angiogram 7 mo later revealed a high-flow, right superior temporal cortical arteriovenous malformation (AVM). The DAVF unfortunately had also progressed. Endovascular occlusion of both lesions was attempted but was not successful. Subsequently, microsurgical resection for both the vascular malformations was performed with careful pre- and intraoperative planning to obtain a successful clinical and angiographic result. In this video, we summarize diagnostic and therapeutic nuances that have broad implications for the workup of ICH and the strategic management of a unique scenario involving a brain AVM and high-grade cranial dural fistula in the same patient. Prior to each procedure, informed consent was obtained from the patient, which includes consent for publication.
Biomechanical Evaluation of Suture Anchor versus Transosseous Tunnel Patellar Tendon Repair Techniques
Sherman, Seth L. , Black, Brandee S., Mooberry, Matthew A., Freeman, Katie L., Gulbrandsen, Trevor R. , Milles, Jeffrey L., Evans, Laura , Flood, David, Mooberry, Matthew, Evans, Laura, Pfeiffer, Ferris M.

Mayo Clinic

The Journal of Knee Surgery | September 6, 2018 | Volume: 32 | Issue: 08 | Pages: 825-832

10.1055/s-0038-1669790 | PMID 30189438 Get It

Abstract The objective of this study is to compare the cyclic loading strength and ultimate failure load in suture anchor repair versus transosseous tunnel repair of patellar tendons using a cadaver model. Twelve cadaveric patella specimens were used (six matched pairs). Dual-energy X-ray absorptiometry (DXA) measurements were performed to ensure equal bone quality among groups. All right knees were assigned to the suture anchor repair group (n = 6), whereas all left knees were assigned to the transosseous bone tunnel group (n = 6). Suture type and repair configuration were equivalent. After the respective procedures were performed, each patella was mounted into a gripping jig. Tensile load was applied at a rate of 1 Hz between magnitudes of 50 and 150 N, 50 and 200 N, 50 and 250 N, and tensile load at a rate of 0.1 mm/s until failure. Failure was defined as a sharp deviation in the linear load versus displacement curve, and failure mode was recorded. DXA measurements demonstrated equivalence of bone quality between the two groups (p > 0.05). During cyclic load testing, there was only a statistically significant difference between the groups with regard to cyclic loading at the 50 to 200 N loading cycle (p = 0.010). There was no statistically significant difference between the groups with regard to ultimate load to failure (p = 0.43). Failure mode within the suture anchor cohort occurred through anchor pullout except for one, which failed through the tendon. All specimens within the transosseous cohort failed through the midsubstance of the tendon except for one, which failed through suture breakage. Suture anchor repair demonstrated a similar biomechanical profile regarding cyclic loading and ultimate load to failure when compared with “gold standard” transosseous tunnel patellar tendon repair with a trend toward less gapping in the suture anchor group. Using suture anchors for repair of the patella tendon has similar biomechanical properties to transpatellar tunnels but may provide other clinical advantages.
The Mayo Clinic experience in patients with metastatic melanoma who have failed previous pembrolizumab treatment.
Yan, Yiyi , Failing, Jarrett, Leontovich, Alexey A. , Block, Matthew S. , Kottschade, Lisa A. , Dronca, Roxana , Markovic, Svetomir, McWilliams, Robert R. , Markovic, Svetomir N.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e21014-e21014

10.1200/jco.2016.34.15_suppl.e21014 Get It

Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.
Tandon, Nidhi , Lacy, Martha Q. , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Zeldenrust, Steven R., Lust, John A., Kumar, Shaji , Buadi, Francis K. , Leung, Nelson , Go, Ronald S. , Dingli, David , Gertz, Morie A. , Lin, Yi , Dispenzieri, Angela , Drake, Matthew T. , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8053-8053

10.1200/jco.2016.34.15_suppl.8053 Get It

Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.
Crump, Michael , Neelapu, Sattva S. , Neste, Éric Van Den, Ahmed, Mohamed , Zhu, Liting , Feng, Lei, Navale, Lynn, Wiezorek, Jeffrey S., Go, William Y., Gisselbrecht, Christian , Farooq, Umar , Kuruvilla, John , Link, Brian K. , Hay, Annette E. , Cerhan, James R. , Boussetta, Sami , Maurer, Matthew J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7516-7516

10.1200/jco.2016.34.15_suppl.7516 Get It

NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE.
Wolin, Edward M. , Chasen, Beth, Kulke, Matthew H. , Caplin, Martyn , Baum, Richard P. , Hobday, Timothy J. , Hendifar, Andrew , Öberg, Kjell E., Sierra, Maribel Lopera , Kwekkeboom, Dik J., Ruszniewski, Philippe, Krenning, Eric P. , Kunz, Pamela L. , Strosberg, Jonathan , Bushnell, David

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4005-4005

10.1200/jco.2016.34.15_suppl.4005 Get It

Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
Frankel, Paul , Herzog, Josef , Cynthia, X. , Cigler, Tessa, Cream, Leah, Harvey, Harold A., Nanda, Rita , Chew, Helen K. , Tongeren, Lily R. Van, Ferry‐Galow, Katherine V., Somlo, George, Weitzel, Jeffrey N. , Arun, Banu , Beumer, Jan Hendrik , Sparano, Joseph A. , Vahdat, Linda T. , Goetz, Matthew P. , Gandara, David R. , Piekarz, Richard , Synold, Timothy Walter

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2549-2549

10.1200/jco.2016.34.15_suppl.2549 Get It

A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.
O’Neill, Anne, Schneider, Bryan P. , Flockhart, David A., Skaar, Todd C. , Liu, Minetta C. , Lohrisch, Caroline , Sologuren, Carlos Vallejos, Villa, Diego , Silverman, Paula , Cheema, P. , Moore, Dennis F., Stearns, Vered , Goetz, Matthew P. , Sparano, Joseph A. , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 546-546

10.1200/jco.2016.34.15_suppl.546 Get It

Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).
Cynthia, X. , Bose, Ron , Pegram, Mark D. , Blackwell, Kimberly , Bédard, Philippe L. , Hayes, Daniel F. , Russell, Christy , Forero, Andres , Bumb, Caroline, Al‐Kateb, Hussam , Gao, Feng , Freedman, Rachel A. , Goetz, Matthew P. , Niravath, Polly Ann , Tripathy, Debu , Cobleigh, Melody , Pluard, Timothy , Anders, Carey K. , Naughton, Michael J. , Ellis, Matthew J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 516-516

10.1200/jco.2016.34.15_suppl.516 Get It

Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma.
Dronca, Roxana , Harrington, Susan M. , Kottschade, Lisa A. , Koo, Chi Wan , Block, Matthew S. , Nevala, Wendy K. , Mansfield, Aaron S. , Liu, Xin , Enninga, Elizabeth Ann L. , McWilliams, Robert R. , Markovic, Svetomir N. , Dong, Haidong

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 11534-11534

10.1200/jco.2017.35.15_suppl.11534 Get It

11534 Background: To date, there are no validated blood-based biomarkers of predicting response to PD-1 blockade. We previously reported that Bim is a downstream signaling molecule of the PD-1 pathway, and that measurement of Bim levels in circulating T-cells may predict and monitor responses to anti–PD-1 therapy in melanoma. We have identified the existence of sPD-L1 in cancer patients and showed that the sPD-L1 is biologically active and capable of triggering apoptosis in activated T-cells. Here we evaluated T cell Bim and sPD-L1 in the peripheral blood (PB) as biomarkers of response in a cohort of patients with metastatic melanoma and lung cancer undergoing anti-PD1 therapy. Methods: 60 pts treated with anti-PD-1 had PB collected at baseline and at radiographic tumor evaluation. Frequencies of Bim+ T cells and Bim median fluorescence intensity (MFI) were measured by flow cytometry in gated tumor-reactive CD11ahighPD1+ CD8+ T cells. We also measured levels of sPD-L1 at baseline and serially during treatment with sPD-L1 ELISA. Baseline Bim and sPD-L1 levels and percent change in Bim levels in patients (pts) who had a radiographic response (CR/PR) were compared to those who had progressive disease (PD) at 12 wks. Results: Similarly to previously reported preliminary data, pts with objective response (CR/PR, 15/60) after 4 cycles of anti-PD1 therapy had higher frequency of Bim T cells at baseline compared to pts with PD (16/60) (mean 43% vs. 30%, P = 0.0484). The frequencies of Bim+ T cells decreased significantly after the first 3 months of treatment in responders compared with progressors (mean -16% vs. + 40% P = 0.0111). High baseline sPD-L1 were associated with progression on anti-PD1 therapy (mean 2.8 ng/mL vs. 0.7 ng/mL, p = 0.07, n = 13) and the levels increased by the first tumor assessment in patients resistant to anti-PD-1. Conclusions: Measurements of Bim and sPD-L1 levels may help to select patients who are likely to benefit from anti-PD1 monotherapy versus combinatorial strategies, and provide a new non-invasive way to monitor response to anti-PD-1 blockade. A larger validation study is underway.